JP2020533302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533302A5 JP2020533302A5 JP2020513684A JP2020513684A JP2020533302A5 JP 2020533302 A5 JP2020533302 A5 JP 2020533302A5 JP 2020513684 A JP2020513684 A JP 2020513684A JP 2020513684 A JP2020513684 A JP 2020513684A JP 2020533302 A5 JP2020533302 A5 JP 2020533302A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- therapeutic agent
- prophylactic
- mic
- glp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims 15
- 229940124597 therapeutic agent Drugs 0.000 claims 15
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims 11
- 101710194460 Growth/differentiation factor 15 Proteins 0.000 claims 11
- 230000000069 prophylactic effect Effects 0.000 claims 11
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 8
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 8
- -1 GLP-1 compound Chemical class 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims 3
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims 2
- 108010019598 Liraglutide Proteins 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 229960002701 liraglutide Drugs 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 229950011186 semaglutide Drugs 0.000 claims 2
- 108010060325 semaglutide Proteins 0.000 claims 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17190270.3 | 2017-09-10 | ||
| EP17190270 | 2017-09-10 | ||
| PCT/EP2018/074263 WO2019048660A1 (en) | 2017-09-10 | 2018-09-10 | MIC-1 AND GLP-1 FOR USE IN THE TREATMENT OF OBESITY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020533302A JP2020533302A (ja) | 2020-11-19 |
| JP2020533302A5 true JP2020533302A5 (enExample) | 2021-09-24 |
Family
ID=59901361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513684A Withdrawn JP2020533302A (ja) | 2017-09-10 | 2018-09-10 | 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11260108B2 (enExample) |
| EP (1) | EP3681529A1 (enExample) |
| JP (1) | JP2020533302A (enExample) |
| CN (1) | CN111163795A (enExample) |
| MA (1) | MA50233A (enExample) |
| WO (1) | WO2019048660A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| JP7536030B2 (ja) * | 2019-03-08 | 2024-08-19 | アムジエン・インコーポレーテツド | 増殖分化因子１５併用療法 |
| ES3061099T3 (en) | 2019-10-04 | 2026-03-31 | Amgen Inc | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| KR102899743B1 (ko) * | 2019-12-11 | 2025-12-12 | 주식회사 엘지화학 | O-글리코실화 가능한 폴리펩타이드 영역 및 gdf15를 포함하는 융합 폴리펩타이드 |
| WO2021136223A1 (en) | 2019-12-31 | 2021-07-08 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
| CN111234015B (zh) * | 2020-02-12 | 2021-04-06 | 康维众和(中山)生物药业有限公司 | 用于延长药物半衰期的抗体、其融合蛋白和应用 |
| EP4237438A4 (en) | 2020-10-27 | 2024-11-27 | Beijing QL Biopharmaceutical Co., Ltd. | GDF15 FUSION PROTEINS AND THEIR USE |
| EP4351627A4 (en) * | 2021-05-21 | 2025-06-04 | Yuhan Corporation | COMPOSITION FOR COMBINATION THERAPY COMPRISING A GROWTH DIFFERENTIATION FACTOR 15 VARIANT AND A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| DK2441466T3 (da) | 2004-04-13 | 2014-10-27 | St Vincents Hosp Sydney | MIC-1-inhiberende middel |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US20130035281A1 (en) * | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| JP5977814B2 (ja) | 2011-04-08 | 2016-08-24 | アムジエン・インコーポレーテツド | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法 |
| KR20140125803A (ko) | 2012-01-26 | 2014-10-29 | 암젠 인크 | 성장 분화 인자 15(gdf-15) 폴리펩타이드들 |
| JP6254146B2 (ja) * | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| CA2899170C (en) | 2013-01-30 | 2022-08-02 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| LT3027642T (lt) | 2013-07-31 | 2020-10-12 | Amgen Inc. | Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai |
| EP3157947A1 (en) | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| WO2015197446A1 (en) | 2014-06-24 | 2015-12-30 | Novo Nordisk A/S | Mic-1 fusion proteins and uses thereof |
| JP6704358B2 (ja) | 2014-07-30 | 2020-06-03 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | 代謝障害を治療するための組成物および使用方法 |
| CN106687128B (zh) | 2014-10-31 | 2022-05-10 | Ngm生物制药有限公司 | 用于治疗代谢病症的组合物和方法 |
| US20190000923A1 (en) | 2015-12-22 | 2019-01-03 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| WO2017121865A1 (en) | 2016-01-15 | 2017-07-20 | Novo Nordisk A/S | Mic-1 receptor and uses thereof |
-
2018
- 2018-09-10 JP JP2020513684A patent/JP2020533302A/ja not_active Withdrawn
- 2018-09-10 CN CN201880058528.0A patent/CN111163795A/zh not_active Withdrawn
- 2018-09-10 US US16/645,828 patent/US11260108B2/en not_active Expired - Fee Related
- 2018-09-10 WO PCT/EP2018/074263 patent/WO2019048660A1/en not_active Ceased
- 2018-09-10 EP EP18769323.9A patent/EP3681529A1/en not_active Withdrawn
- 2018-09-10 MA MA050233A patent/MA50233A/fr unknown